A multicenter clinical trial of piperacillin/tazobactam in burn infection / 中华烧伤杂志

ABSTRACT

<p><b>OBJECTIVE</b>To evaluate the efficacy of piperacillin/tazobactam in the management of burn infection.</p><p><b>METHODS</b>Sixty-three burn patients were enrolled in the study with burn sepsis or burn area more than 50%TBSA or full skin loss more than 30% TBSA. The administration regime of the antibiotics was 4.5 g intravenously administered every 8 hours in the treatment of burn sepsis or in the prophylactic management. The effectiveness was identified when the septic symptoms disappeared or focal infection did not develop into sepsis.</p><p><b>RESULTS</b>The overall clinical efficacy was 90.4%, and success in sepsis (control) was 75%. Furthermore, 95.7% of the focal infection was prevented from developing into systemic infection. The bacterial clearance rates were 71.4% and 51.4% in treatment and prophylaxis groups, respectively.</p><p><b>CONCLUSION</b>Piperacillin/taxobactam was effective in the treatment and/or prophylaxis of burn sepsis caused by bacteria susceptible to it, so it could be applied empirically.</p>